Induced pluripotent stem cells from patients with huntington’s disease show CAG repeat expansion associated phenotypes

Cell Stem Cell

Volumn 11, Issue 2, 2012, Pages 264-278

  Mattis, Virginia B ^a   Svendsen, Soshana P ^a   Ebert, Allison ^b   Svendsen, Clive N ^a   King, Alvin R ^c   Casale, Malcolm ^c   Winokur, Sara T ^c   Batugedara, Gayani ^c   Vawter, Marquis ^c   Donovan, Peter J ^c   Lock, Leslie F ^c   Thompson, Leslie M ^c   Zhu, Yu ^d   Fossale, Elisa ^d   Atwal, Ranjit Singh ^d   Gillis, Tammy ^d   Mysore, Jayalakshmi ^d   Li, Jian Hong ^d   Seong, Ihnsik ^d   Shen, Yiping ^d   Chen, Xiaoli ^d   Wheeler, Vanessa C ^d   Macdonald, Marcy E ^d   Gusella, James F ^d   Akimov, Sergey ^e   Arbez, Nicolas ^e   Juopperi, Tarja ^f   Ratovitski, Tamara ^e   Chiang, Jason H ^f   Kim, Woon Roung ^f   Chighladze, Eka ^e   Watkin, Erin ^e   Zhong, Chun ^f   Makri, Georgia ^f   Cole, Robert N ^g   Margolis, Russell L ^d,g   Song, Hongjun ^f   Ming, Guoli ^f   Ross, Christopher A ^e,g,h   Kaye, Julia A ^i,j   Daub, Aaron ^i,j   Sharma, Punita ^i,j   Mason, Amanda R ^i,j   Finkbeiner, Steven ^i,j   Yu, Junying ^k   Thomson, James A ^l   Rushton, David ^m   Brazier, Stephen P ^m   Battersby, Alysia A ^m   Redfern, Amanda ^m   Tseng, Hsui Er ^m   Harrison, Alexander W ^m   Kemp, Paul J ^m   Allen, Nicholas D ^m   Onorati, Marco ⁿ   Castiglioni, Valentina ⁿ   Cattaneo, Elena ⁿ   Arjomand, Jamshid ^o   more..

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Division of Neurobiology   (United States)

^f Institute for Cell Engineering   (United States)

^g Department of Biological Chemistry ^*  (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k Cellular Dynamics International   (United States)

^l MORGRIDGE INSTITUTE FOR RESEARCH   (United States)

^m CARDIFF UNIVERSITY   (United Kingdom)

ⁿ UNIVERSITY OF MILAN   (Italy)

^o CHDI MANAGEMENT CHDI FOUNDATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR;

ARTICLE; CAG REPEAT; CELL ADHESION; CELL DEATH; CELL DIFFERENTIATION; CELL LINE; CELL METABOLISM; CELL STRESS; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; ELECTROPHYSIOLOGY; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MICROARRAY ANALYSIS; NERVE CELL; NEURAL STEM CELL; PATHOPHYSIOLOGY; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL;

EID: 84864628471     PISSN: 19345909     EISSN: 18759777     Source Type: Journal    
DOI: 10.1016/j.stem.2012.04.027     Document Type: Article

References (49)

1. A postol BL, Simmons DA, Zuccato C, Illes K, Pallos J, Casale M, Conforti P, Ramos C, Roarke M, Kathuria S, et al. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci. 2008; 39:8-20. [PubMed: 18602275]
2. Arrasate M, Finkbeiner S. Automated microscope system for determining factors that predict neuronal fate. Proc Natl Acad Sci U S A. 2005; 102:3840-3845. [PubMed: 15738408]
3. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004; 431:805-810. [PubMed: 15483602]
4. Aubry L, Bugi A, Lefort N, Rousseau F, Peschanski M, Perrier AL. Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc Natl Acad Sci U S A. 2008; 105:16707-16712. [PubMed: 18922775]
5. Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya Y, Hayward SD, Moran TH, Montell C, Ross CA, et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron. 2005; 47:29-41. [PubMed: 15996546]
6. Behrens PF, Franz P, Woodman B, Lindenberg KS, Landwehrmeyer GB. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain. 2002; 125:1908-1922. [PubMed: 12135980]
7. Blain JF, Paradis E, Gaudreault SB, Champagne D, Richard D, Poirier J. A role for lipoprotein lipase during synaptic remodeling in the adult mouse brain. Neurobiol Dis. 2004; 15:510-519. [PubMed: 15056458]
8. Bradley CK, Scott HA, Chami O, Peura TT, Dumevska B, Schmidt U, Stojanov T. Derivation of Huntington's disease-affected human embryonic stem cell lines. Stem Cells Dev. 2011; 20:495-502. [PubMed: 20649476]
9. Camnasio S, Carri AD, Lombardo A, Grad I, Mariotti C, Castucci A, Rozell B, Riso PL, Castiglioni V, Zuccato C, Rochon C, Takashima Y, Diaferia G, Biunno I, Gellera C, Jaconi M, Smith A, Hovatta O, Naldini L, Di Donato S, Feki A, Cattaneo E. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiology of Disease. 2012; 46:41-51. 2012. [PubMed: 22405424]
10. Consortium TH. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993; 72:971-983. [PubMed: 8458085]
11. Ebert AD, Yu J, Rose FF Jr, Mattis VB, Lorson CL, Thomson JA, Svendsen CN. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature. 2009; 457:277-280. [PubMed: 19098894]
12. Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G, Dufour N, Guillermier M, Brouillet E, Hantraye P, et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum Mol Genet. 2010; 19:3053-3067. [PubMed: 20494921]
13. Fan MM, Raymond LA. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol. 2007; 81:272-293. [PubMed: 17188796]
14. Gines S, Paoletti P, Alberch J. Impaired TrkB-mediated ERK1/2 activation in huntington disease knock-in striatal cells involves reduced p52/p46 Shc expression. J Biol Chem. 2010; 285:21537-21548. [PubMed: 20442398]
15. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet. 2006; 15:965-977. [PubMed: 16467349]
16. Jacobsen JC, Gregory GC, Woda JM, Thompson MN, Coser KR, Murthy V, Kohane IS, Gusella JF, Seong IS, MacDonald ME, et al. HD CAG-correlated gene expression changes support a simple dominant gain of function. Hum Mol Genet. 2011; 20:2846-2860. [PubMed: 21536587]
17. Karasinska JM, Hayden MR. Cholesterol metabolism in Huntington disease. Nat Rev Neurol. 2011; 7:561-572. [PubMed: 21894212]
18. Koch P, Breuer P, Peitz M, Jungverdorben J, Kesavan J, Poppe D, Doerr J, Ladewig J, Mertens J, Tuting T, et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature. 2011; 480:543-546. [PubMed: 22113611]
19. Langbehn DR, Hayden MR, Paulsen JS. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet. 2010; 153B:397-408. [PubMed: 19548255]
20. Lievens JC, Rival T, Iche M, Chneiweiss H, Birman S. Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. Hum Mol Genet. 2005
21. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Spektor BS, Penney EB, Schilling G, et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet. 2000; 9:1259-1271. [PubMed: 10814708]
22. Mattis VB, Svendsen CN. Induced pluripotent stem cells: a new revolution for clinical neurology? Lancet Neurol. 2011; 10:383-394. [PubMed: 21435601]
23. Miller JP, Holcomb J, Al-Ramahi I, de Haro M, Gafni J, Zhang N, Kim E, Sanhueza M, Torcassi C, Kwak S, et al. Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. Neuron. 2010; 67:199-212. [PubMed: 20670829]
24. Molero AE, Gokhan S, Gonzalez S, Feig JL, Alexandre LC, Mehler MF. Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease. Proc Natl Acad Sci U S A. 2009; 106:21900-21905. [PubMed: 19955426]
25. Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P, Kee K, Schule B, Dolmetsch RE, Langston W, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell. 2011; 8:267-280. [PubMed: 21362567]
26. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ. Disease-specific induced pluripotent stem cells. Cell. 2008; 134:877-886. [PubMed: 18691744]
27. Pruunsild P, Sepp M, Orav E, Koppel I, Timmusk T. Identification of cis-elements and transcription factors regulating neuronal activity-dependent transcription of human BDNF gene. J Neurosci. 2011; 31:3295-3308. [PubMed: 21368041]
28. Reis SA, Thompson MN, Lee JM, Fossale E, Kim HH, Liao JK, Moskowitz MA, Shaw SY, Dong L, Haggarty SJ, et al. Striatal neurons expressing full-length mutant huntingtin exhibit decreased Ncadherin and altered neuritogenesis. Hum Mol Genet. 2011; 20:2344-2355. [PubMed: 21447599]
29. Rosenblatt A, Kumar BV, Mo A, Welsh CS, Margolis RL, Ross CA. Age, CAG repeat length, and clinical progression in Huntington's disease. Mov Disord. 2012; 27:272-276. [PubMed: 22173986]
30. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med. 2004; 10(Suppl):S10-S17. [PubMed: 15272267]
31. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011; 10:83-98. [PubMed: 21163446]
32. Ross CA, Thompson LM. Transcription meets metabolism in neurodegeneration. Nat Med. 2006; 12:1239-1241. [PubMed: 17088887]
33. Royer B, Soares DC, Barlow PN, Bontrop RE, Roll P, Robaglia-Schlupp A, Blancher A, Levasseur A, Cau P, Pontarotti P, et al. Molecular evolution of the human SRPX2 gene that causes brain disorders of the Rolandic and Sylvian speech areas. BMC Genet. 2007; 8:72. [PubMed: 17942002]
34. Seibler P, Graziotto J, Jeong H, Simunovic F, Klein C, Krainc D. Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J Neurosci. 2011; 31:5970-5976. [PubMed: 21508222]
35. Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M, Gusella JF, Laramie JM, Myers RH, Lesort M, et al. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet. 2005; 14:2871-2880. [PubMed: 16115812]
36. Shelbourne PF, Keller-McGandy C, Bi WL, Yoon SR, Dubeau L, Veitch NJ, Vonsattel JP, Wexler NS, Arnheim N, Augood SJ. Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain. Hum Mol Genet. 2007; 16:1133-1142. [PubMed: 17409200]
37. Stine OC, Pleasant N, Franz ML, Abbott MH, Folstein SE, Ross CA. Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. Hum Mol Genetics. 1993; 2:1547-1549.
38. Svendsen CN, ter Borg MG, Armstrong RJ, Rosser AE, Chandran S, Ostenfeld T, Caldwell MA. A new method for the rapid and long term growth of human neural precursor cells. J Neurosci Methods. 1998; 85:141-152. [PubMed: 9874150]
39. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomodo K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131:861-872. [PubMed: 18035408]
40. Takata K, Kitamura Y, Tsuchiya D, Kawasaki T, Taniguchi T, Shimohama S. High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. J Neurosci Res. 2004; 78:880-891. [PubMed: 15499593]
41. Tunez I, Sanchez-Lopez F, Aguera E, Fernandez-Bolanos R, Sanchez FM, Tasset-Cuevas I. Important Role of Oxidative Stress Biomarkers in Huntington's Disease. J Med Chem. 2011; 54:5602-5606. [PubMed: 21678912]
42. Vonsattel JP, Keller C, Del Pilar Amaya M. Neuropathology of Huntington's disease. Handb Clin Neurol. 2008; 89:599-618. [PubMed: 18631782]
43. Walker FO. Huntington's disease. Lancet. 2007; 369:218-228. [PubMed: 17240289]
44. Xu EH, Tang Y, Li D, Jia JP. Polymorphism of HD and UCHL-1 genes in Huntington's disease. J Clin Neurosci. 2009; 16:1473-1477. [PubMed: 19683447]
45. Yu J, Hu K, Smuga-Otta K, Tian S, Stewart R, Slukvin I, Thomson JA. Human induced pluripotent stem cells free of vector and transgene sequences. Science. 2009; 324:797-801. [PubMed: 19325077]
46. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318:1917-1920. [PubMed: 18029452]
47. Zhang N, An MC, Montoro D, Ellerby LM. Characterization of Human Huntington's Disease Cell Model from Induced Pluripotent Stem Cells. PLoS Curr. 2010; 2:RRN1193. [PubMed: 21037797]
48. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009; 5:311-322. [PubMed: 19498435]
49. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev. 2010; 90:905-981. [PubMed: 20664076]